By David Wainer
Big pharmaceutical stocks mostly rose after President Trump's executive order exempted medicines from new tariffs. Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play.
Still, drugmakers aren't in the clear. Trump singled them out in his remarks Wednesday, saying: "The pharmaceutical companies are going to come roaring back... because if they don't, they got a big tax to pay."
That underscores Trump's "continued appetite to effect change in the industry," said UBS analyst Trung Huynh. One possible scenario is Trump introduces tariffs specifically targeting pharma-either all at once, or in stages-said Huynh. The president could also pursue tax reform aimed at the industry's offshore tax shelters.
For now, pharma is breathing a sigh of relief. But the reprieve may be temporary.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
April 03, 2025 10:30 ET (14:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。